Docoh
Loading...

VERA Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful, including lupus nephritis, a severe renal manifestation of systemic lupus erythematosus. For more information, please visit www.veratx.com.

VERA stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

15 Aug 21
21 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Cash on hand (at last report) 91.97M 91.97M
Cash burn (monthly) (positive/no burn) 1.95M
Cash used (since last report) n/a 7.28M
Cash remaining n/a 84.69M
Runway (months of cash) n/a 43.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
13 Jul 21 Sean Grant Stock Option Class A Common Stock Grant Acquire A No No 14.87 180,000 2.68M 180,000
18 May 21 Cheng Andrew Class A Common Stock Conversion Acquire C Yes No 0 17,488 0 17,488
18 May 21 Cheng Andrew Series C Preferred Stock Class A Common Stock Conversion Dispose C Yes No 0 17,488 0 0
18 May 21 Enright Patrick G Class A Common Stock Buy Acquire P Yes No 11 909,090 10M 3,096,594
18 May 21 Enright Patrick G Class A Common Stock Conversion Acquire C Yes No 0 2,187,504 0 2,187,504
18 May 21 Enright Patrick G Series C Preferred Stock Class A Common Stock Conversion Dispose C Yes No 0 2,187,504 0 0
18 May 21 Seidenberg Beth C Class A Common Stock Conversion Acquire C Yes No 0 818,984 0 1,343,152
18 May 21 Seidenberg Beth C Class A Common Stock Conversion Acquire C Yes No 0 100,526 0 524,168
18 May 21 Seidenberg Beth C Class A Common Stock Conversion Acquire C Yes No 0 423,642 0 423,642
18 May 21 Seidenberg Beth C Series C Preferred Stock Class A Common Stock Conversion Dispose C Yes No 0 818,984 0 0

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

93.4% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 23 0 NEW
Opened positions 23 0 NEW
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 247.82M 0 NEW
Total shares 19.58M 0 NEW
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
FMR 3.12M $38.48M NEW
Longitude Capital Partners IV 3.1M $38.24M NEW
Abingworth 2.96M $38.51M NEW
Sofinnova Investments 2.91M $38.65M NEW
Sofinnova Venture Partners X 2.91M $36M NEW
Citadel Advisors 1.74M $22.17M NEW
KPCB XVI Associates 1.34M $16.03M NEW
Octagon Capital Advisors 1.13M $15.01M NEW
Millennium Management 81.45K $1.08M NEW
Parkman Healthcare Partners 75.64K $1M NEW
Largest transactions
Shares Bought/sold Change
FMR 3.12M +3.12M NEW
Longitude Capital Partners IV 3.1M +3.1M NEW
Abingworth 2.96M +2.96M NEW
Sofinnova Investments 2.91M +2.91M NEW
Sofinnova Venture Partners X 2.91M +2.91M NEW
Citadel Advisors 1.74M +1.74M NEW
KPCB XVI Associates 1.34M +1.34M NEW
Octagon Capital Advisors 1.13M +1.13M NEW
Millennium Management 81.45K +81.45K NEW
Parkman Healthcare Partners 75.64K +75.64K NEW

Financial report summary

?
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg

Proxies

No filings

Reddit threads

Pro users get this 30m faster